Dr. Lynn D. Hudson Chief Science Officer for the Critical Path Institute (C-Path) and Executive Director of the Multiple Sclerosis Outcome Assessments Consortium Dr. Lynn D. Hudson serves as the Chief Science Officer for the Critical Path Institute (C-Path) and Executive Director of the Multiple Sclerosis Outcome Assessments Consortium. She started at C-Path by overseeing [...]
Sheldon Whitehouse United States Senator for Rhode Island Sheldon Whitehouse has made reforming our broken health care system a hallmark of his career. During his time as Rhode Island’s Attorney General he founded the Rhode Island Quality Institute, a collaborative effort between health care providers, insurers, and government that has pioneered efforts to expand the [...]
Peter L. Saltonstall President and CEO, NORD, Peter is NORD’s President and Chief Executive Officer. He has over 30 years of healthcare experience in both for-profit and not-for-profit environments, as well as extensive federal and commercial market knowledge. Peter has held senior positions within a number of major academic medical centers and organizations, including Harvard's [...]
Anders Olauson President, EPF Mr. Anders Olauson is founder, chairman and chief executive officer of the Agrenska Centre in Sweden. His vision behind setting up the Agrenska Centre in 1989 was his profound concern for children affected by rare conditions and their families and the need to move towards a fairer society that embraces and [...]
Nancy Berg CEO, ISPOR Nancy Berg has nearly 30 years of experience in health care, scientific, and technical association leadership, and has been an entrepreneur and business consultant to both commercial and nonprofit organizations. Ms Berg has been chief executive officer (CEO) and executive director of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) [...]
David A. Dworaczyk, Ph.D. Director, Life and Health Sciences Strategic Development, Oracle Health Sciences Dr. Dworaczyk has done extensive work with numerous Healthcare, Pharma, Biotech, Diagnostic and CRO focused Venture and Private Equity investment groups assessing and evaluating investment opportunities from an operational, strategic and business potential perspective. He is currently the Director of Life [...]
John Peter Mary Wubbe Secretary General & Independent board member, Epossi John Peter Mary Wubbe is a healthcare professional, have studied MSc European Public Health, specializing in Governance. Mr. Wubbe has created EuDiPPA to improve data governance. Mr Wubbe expertise lies in Genomics-Robotics-Informatics-Biometrics (GRIBs) and Phenotype and Genotype Datasets. He is deeply knowledgeable in the [...]
Pierre Meulien Executive Director, Innovative Medicines Initiative Pierre Meulien joined IMI as Executive Director in September 2015. Prior to that Pierre Meulien was President and Chief Executive Officer (CEO) of Genome Canada, a not-for-profit organisation that connects ideas and people across public and private sectors to find new uses for genomics and invests in large-scale [...]
Sabine Atzor Director Regulatory Affairs, part time seconded from F.Hoffmann-La Roche to EFPIA Sabine Atzor joined F. Hoffmann-La Roche Ltd in Basel as Head of EU Regulatory Policies in 2010. In this function she has been contributing to various policy discussions within EFPIA, in particular on the new EU Clinical Trials Regulation, where she has [...]
Sandra A. Milligan, MD, JD President, DIA Senior Vice President, Head of Regulatory Affairs and Safety Merck Research Laboratories Dr. Milligan currently serves as Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety of Merck, consisting of the global Regulatory, Safety and CMC functions of Merck Research Laboratories. She previously served as [...]